Now that Merck KGAA's oral multiple sclerosis drug Mavenclad (cladribine) has finally got European approval, the German group is now looking at how to make inroads into what is already a crowded market.
Mavenclad has been given the green light for the treatment of highly active relapsing MS and Merck notes that it...







